Literature DB >> 10541322

Bone and collagen markers in preterm infants: relationship with growth and bone mineral content over the first 10 weeks of life.

P M Crofton1, A Shrivastava, J C Wade, R Stephen, C J Kelnar, A J Lyon, N McIntosh.   

Abstract

In a longitudinal study of 25 preterm infants, we have examined the relationship of bone-specific alkaline phosphatase (ALP), C-terminal propeptide of type I collagen (PICP), N-terminal propeptide of type III procollagen (P3NP), C-terminal telopeptide of type I collagen, urinary pyridinoline (Pyd) and deoxypyridinoline (Dpd), with rates of gain in weight, length, and lower leg length and with bone mineral content (BMC), all measured at weekly intervals over the first 10 wk of life. Concentrations of all collagen markers were 10-fold higher than in older children. Each marker showed a distinctive pattern of postnatal change, with early increases in PICP and P3NP and decreases in ICTP reflecting postnatal growth. Once markers had reached a plateau during weeks 4-10, P3NP was positively correlated, whereas Pyd and Dpd were negatively correlated with rate of weight gain (r = +0.44, -0.46, and -0.40, respectively, p < 0.05). P3NP was also positively correlated with overall linear growth (r = +0.44, p < 0.05). PICP was strongly correlated with mean BMC (r = +0.63,p < 0.01) and with total BMC attained by the end of the study period (r = +0.81, p < 0.001). Bone ALP was positively correlated with the rate of bone mineral accretion (r = +0.55, p = 0.01). We conclude that the marker of soft-tissue collagen formation, P3NP, is a good marker for overall ponderal and linear growth in preterm infants, whereas the markers of collagen breakdown, Pyd and Dpd, have inverse relationships with weight gain. The osteoblast markers, PICP and bone ALP, seem to be good surrogate markers for bone mineralization in preterm infants. Markers may provide information on whole-body turnover of bone and collagen that is complementary to traditional physical measures of growth and bone mineralization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10541322     DOI: 10.1203/00006450-199911000-00015

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Bone mineralisation in premature infants cannot be predicted from serum alkaline phosphatase or serum phosphate.

Authors:  J Faerk; B Peitersen; S Petersen; K F Michaelsen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-09       Impact factor: 5.747

Review 2.  Unexplained fractures in infancy: looking for fragile bones.

Authors:  Nick Bishop; Alan Sprigg; Ann Dalton
Journal:  Arch Dis Child       Date:  2007-03       Impact factor: 3.791

3.  Changes in markers of bone metabolism during dexamethasone treatment for chronic lung disease in preterm infants.

Authors:  P C Ng; C W K Lam; G W K Wong; C H Lee; P S Cheng; T F Fok; I H S Chan; E Wong; K Cheung; S Y Lee
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-01       Impact factor: 5.747

4.  Assessment of the place of tubular reabsorption of phosphorus in the diagnosis of osteopenia of prematurity.

Authors:  Duygu Besnili Acar; Sultan Kavuncuoğlu; Merih Çetinkaya; Ercüment Petmezci; Mesut Dursun; Orhan Korkmaz; Emel Kayrak Altuncu
Journal:  Turk Pediatri Ars       Date:  2015-03-01

5.  Levels of bone collagen markers in preterm infants: relation to antenatal glucocorticoid treatment.

Authors:  Eftichia Korakaki; Dimitrios Gourgiotis; Agisilaos Aligizakis; Antonia Manoura; Eleftheria Hatzidaki; Emmanuel Giahnakis; Antonios Marmarinos; Maria Kalmanti; Christina Giannakopoulou
Journal:  J Bone Miner Metab       Date:  2007-04-20       Impact factor: 2.626

6.  Evidence of associations between feto-maternal vitamin D status, cord parathyroid hormone and bone-specific alkaline phosphatase, and newborn whole body bone mineral content.

Authors:  Daphna K Dror; Janet C King; Ellen B Fung; Marta D Van Loan; Erik R Gertz; Lindsay H Allen
Journal:  Nutrients       Date:  2012-02-06       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.